Recbio and Biological E Partner for HPV9 Vaccine in India and Global Markets
Chinese biopharmaceutical company Recbio Technology has signed a deal with Indian firm Biological E to license and transfer technology for the HPV9 vaccine, targeting nine strains of Human Papillomavirus. Biological E will have exclusive rights to commercialize the vaccine in India and participate in global tenders. The partnership aims to address the increasing demand for cervical cancer prevention.
HYDERABAD: Jiangsu Recbio Technology Co. Ltd, a leading Chinese biopharmaceutical firm, has partnered with Hyderabad-based Biological E Limited (BE) for its Recombinant 9-valent HPV (HPV9) vaccine, REC603.
The HPV9 vaccine protects against nine strains of Human Papillomavirus, including those associated with various cancers and genital warts. BE has exclusive rights to commercialize the vaccine in India and participate in global tenders by UNICEF and PAHO.
Recbio will provide the Drug Substance (DS) and transfer formulation, filling, and packaging technologies to BE. They will also share technical expertise for local production and support BE through clinical development and regulatory approvals.
The partnership aims to address the increasing global demand for cervical cancer prevention, with large-scale manufacturing to commence post-technology transfer completion.
Dr. Liu Yong, Recbio’s chairman and CEO, views the deal as a significant step in global expansion. Mahima Datla, MD of BE, emphasizes their commitment to enhancing accessibility and affordability of life-saving vaccines through this partnership.
According to the source: The New Indian Express.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
